Congress in Spain were a major feature of research news last week, including those from Pfizer on it ponsegromab in cancer ...

In a rough day for PARP inhibitors in ovarian cancer, GSK’s Zejula didn’t deliver a life extension benefit in the final ...

The GSK share price has had a rotten few years and now it's heading south yet again. Investor Harvey Jones continues to hang ...

GlaxoSmithKline Pharmaceuticals Ltd. engages in the business of manufacturing, distributing and trading in pharmaceuticals. The company's product portfolio includes prescription medicines and ...

The British pharma said its shot didn’t meet the efficacy goals of a Phase 2 study. Elsewhere, Zealand reported more obesity drug data and Lilly appointed a company veteran as its new CFO.

British drugmaker GSK said on Wednesday its experimental herpes simplex virus (HSV) vaccine candidate failed to meet the main ...

Goldman Sachs analyst Rajan Sharma maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of ...

GSK’s long-acting asthma treatment has been shown to halve the number of attacks in a pair of phase 3 trials, supporting the ...

Everything we covered on WTR over the past seven days, and all you need to know from the world of trademarks to set yourself up for the start of another busy week.

After an initial defeat against the biggest barrier to mRNA flu vaccines—namely, B strains of influenza—GSK has returned with a reformulated candidate that has ...

Hello, everyone, and how are you today? We are doing just fine, thank you, especially since the middle of the week is upon us ...